
Traws Pharma (TRAW) Stock Forecast & Price Target
Traws Pharma (TRAW) Analyst Ratings
Bulls say
Traws Pharma is expected to have a positive outlook due to its strong pipeline of product candidates, multiple sources of revenue from collaboration and licensing agreements, and a moderate weighted average cost of capital of 19.0%. However, potential risks include financing, clinical trial, regulatory, delisting, and bankruptcy risks, which may impact the company's financials and market performance. Additionally, success in their pipeline and a larger addressable market for viruses such as COVID, hantavirus, or Ebola could potentially lead to upside opportunities for the company.
Bears say
Traws Pharma is facing potential setbacks in their TXM influenza program as a result of negative reviews from regulators. The FDA has placed a clinical hold on the U.S. IND for TXM, while the MHRA in the UK has expressed concerns about safety and genotoxicity within the clinical package. This could delay the development of TXM and push the lead program toward additional regulatory work or a backup-candidate strategy.
This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.
Traws Pharma (TRAW) Analyst Forecast & Price Prediction
Start investing in Traws Pharma (TRAW)
Order type
Buy in
Order amount
Est. shares
0 shares